open access publication

Article, 2024

Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial

Radiotherapy and Oncology, ISSN 1879-0887, 0167-8140, Volume 194, Page 110195, 10.1016/j.radonc.2024.110195

Contributors

Høgsbjerg, Kristine Wiborg (Corresponding author) [1] Maae, Else [2] Nielsen, Mette Holck [3] Stenbygaard, Lars Eric [4] Pedersen, Anders Navrsted [5] Yates, Esben Svitzer [1] Berg, Martin [2] Lorenzen, Ebbe Laugaard 0000-0003-1895-733X [3] Jensen, Ingelise [4] Josipovic, Mirjana 0000-0001-8288-162X [5] Thomsen, Mette Skovhus [1] Offersen, Birgitte Vrou [1]

Affiliations

  1. [1] Aarhus University Hospital
  2. [NORA names: Central Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
  3. [2] Vejle Sygehus
  4. [NORA names: Region of Southern Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  5. [3] Odense University Hospital
  6. [NORA names: Region of Southern Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  7. [4] Aalborg University Hospital
  8. [NORA names: North Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
  9. [5] Rigshospitalet
  10. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD]

Abstract

BACKGROUND AND PURPOSE: Partial breast irradiation (PBI)has beenthe Danish Breast Cancer Group(DBCG) standard for selected breast cancer patients since 2016 based onearlyresults from the DBCG PBI trial.During trial accrual, respiratory-gated radiotherapy was introduced in Denmark. This study aims to investigate the effect of respiratory-gating on mean heart dose (MHD). PATIENTS AND METHODS: From 2009 to 2016 the DBCG PBI trial included 230 patientswith left-sided breast cancer receiving external beam PBI, 40 Gy/15 fractions/3 weeks.Localization of the tumor bed on the planning CT scan, the use of respiratory-gating, coverage of the clinical target volume (CTV), and doses to organs at risk were collected. RESULTS: Respiratory-gating was used in 123 patients (53 %). In 176 patients (77 %) the tumor bed was in the upper and in 54 patients (23 %) in the lower breast quadrants. The median MHD was 0.37 Gy (interquartile range 0.26-0.57 Gy), 0.33 Gy (0.23-0.49 Gy) for respiratory-gating, and 0.49 Gy (0.31-0.70 Gy) for free breathing, p < 0.0001. MHD was < 1 Gy in 206 patients (90 %) and < 2 Gy in 221 patients (96 %). Respiratory-gating led to significantly lower MHD for upper-located, but not for lower-located tumor beds, however, all MHD were low irrespective of respiratory-gating. Respiratory-gating did not improve CTV coverage or lower lung doses. CONCLUSIONS: PBI ensured a low MHD for most patients. Adding respiratory-gating further reduced MHD for upper-located but not for lower-located tumor beds but did not influence target coverage or lung doses. Respiratory-gating is no longer DBCG standard for left-sided PBI.

Keywords

CT scan, DBCG, Danish, Denmark, MHD, PBI, accrual, bed, benefits, benefits of respiratory gating, breast, breast cancer, breast cancer patients, breast irradiation, breast quadrants, breathing, cancer, cancer patients, clinical target volume, clinical target volume coverage, coverage, dose, dose to organs, effect, free breathing, gate, irradiation, irradiation trials, left-sided breast cancer, localization, lower breast quadrants, lung, lung dose, organization, partial breast irradiation, patients, planning CT scan, quadrant, radiotherapy, reduced MHD, respiratory gating, respiratory-gated, respiratory-gated radiotherapy, risk, scanning, standards, study, target coverage, target volume, trial accrual, trials, tumor, tumor bed, volume, weeks

Funders

  • Danish Cancer Society
  • Novo Nordisk Foundation

Data Provider: Digital Science